Oncogenes come of age

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 1-9

  Varmus, H ^a   Pao, W ^a   Politi, K ^a   Podsypanina, K ^a   Du, Y C N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ERLOTINIB; GEFITINIB; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TETRACYCLINE DERIVATIVE; BCR ABL PROTEIN; PROTEIN P53;

ALLELE; APOPTOSIS; CANCER; CANCER GENETICS; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DRUG RESISTANCE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; LUNG CANCER; MUTANT; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE RAS; ONCOLOGY WARD; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSGENIC MOUSE; TUMOR GROWTH; VIRUS ONCOGENE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COPY NUMBER VARIATION; GENE EXPRESSION; LEUKEMIA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; MALIGNANT NEOPLASM; MELANOMA; ONCOGENE C MYC; ONCOGENE H RAS; OSTEOSARCOMA;

ADENOCARCINOMA; ANIMALS; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; GENOTYPE; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENES;

EID: 33744780649     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.039     Document Type: Conference Paper

References (61)

1. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Y.R., Sanchez-Cespedes M., Yang S.C., Haasler G.B., Kajdacsy-Balla A., Demeure M.J., and Sidransky D. 2001. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525.
2. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., Kim Y.H., Pollack J.R., Yanagisawa K., Gazdar A., Minna J.D., Kurie J.M., and Carbone D.P. 2005. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65: 226.
3. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949.
4. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., and Weber B.L. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62: 6997.
5. Burgess M.R., Skaggs B.J., Shah N.P., Lee F.Y., and Sawyers C.L. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. 102: 3395.
6. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A., Jr., and Varella-Garcia M. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97: 643.
7. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs W.H., III, Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., and Lockhart D.J. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. 102: 11011.
8. Chen Y.R., Fu Y.N., Lin C.H., Yang S.T., Hu S.F., Chen Y.T., Tsai S.F., and Huang S.F. 2006. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205.
9. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W., 2nd, Cordon-Cardo C., Yancopoulos G.D., and DePinho R.A. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468.
10. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., and Gilliland D.G. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348: 1201.
11. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., and Futreal P.A. 2005. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65: 7591.
12. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., Cox J.D., Ha S.I., Belka G.K., Golant A., Cardiff R.D., and Chodosh L.A. 2001. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7: 235.
13. Deininger M., Buchdunger E., and Druker B.J. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640.
14. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Janne P.A., Januario T., Johnson D.H., Klein P., Miller V.A., Ostland M.A., Ramies D.A., Sebisanovic D., Stinson J.A., Zhang Y.R., Seshagiri S., and Hillan K.J. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23: 5900.
15. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mokuhara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. 102: 3788.
16. Felsher D.W. and Bishop J.M. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4: 199.
17. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., and Varmus H.E. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15: 3249.
18. Flores I., Murphy D.J., Swigart L.B., Knies U., and Evan G.I. 2004. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene 23: 5923.
19. Forgacs E., Zochbauer-Muller S., Olah E., and Minna J.D. 2001. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol. Oncol. Res. 7: 6.
20. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R.P., and Baselga J. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer. J. Clin. Oncol. 21: 2237.
21. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876.
22. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., and Meyerson M. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2: e313.
23. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., and Reddy E.P. 2005. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. 102: 1992.
24. Gunther E.J., Moody S.E., Belka G.K., Hahn K.T., Innocent N., Dugan K.D., Cardiff R.D., and Chodosh L.A. 2003. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17: 488.
25. Hanahan D. 1985. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115.
26. Huettner C.S., Zhang P., Van Etten R.A., and Tenen D.G. 2000. Reversibility of acute B-cell leukaemia induced by BCRABL1. Nat. Genet. 24: 57-60.
27. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., and Felsher D.W. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102.
28. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352: 786.
29. Kris M., Natale R.B., Herbst R., Lynch T., Jr., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K., Cella D., Wolf M., Averbuch S., Ochs J., and Kay A. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. J. Am. Med. Assoc. 290: 2149.
30. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. 102: 7665.
31. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129.
32. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298: 1912.
33. Martin G.S. 1970. Rous sarcoma virus: A function required for the maintenance of the transformed state. Nature 227: 1021.
34. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., Innocent N., Cardiff R.D., Schnall M.D., and Chodosh L.A. 2002. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2: 451.
35. Naik P., Karrim J., and Hanahan D. 1996. The rise and fall of apoptosis during multistage tumorigenesis: Down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 10: 2105.
36. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., and Meyerson M. 2002. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62: 7001.
37. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497.
38. Pao W. and Miller V.A. 2005. EGFR mutations, small molecule kinase inhibitors, and non-small cell lung cancer: Current knowledge and future directions. J. Clin. Oncol. 23: 2556.
39. Pao W., Klimstra D.S., Fisher G.H., and Varmus H.E. 2003. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc. Natl. Acad. Sci. 100: 8764.
40. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2: e73.
41. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Landanyi M., Zakowski M.F., Heelan R.T., Kris M.G., and Varmus H.E. 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2: e17.
42. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. 101: 13306.
43. Parkin D.M., Bray F., and Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74.
44. Parsons D.W., Wang T.L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., and Velculescu V.E. 2005. Colorectal cancer: Mutations in a signalling pathway. Nature 436: 792.
45. Pelengaris S., Khan M., and Evan G.I. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321.
46. Perl A.K., Wilgenbus P., Dahl U., Semb H., and Christofori G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190.
47. Podsypanina K., Li Y., and Varmus H.E. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med. 2: 24.
48. Rosenberg N. and Jolicoeur P. 1997. Retroviral pathogenesis. In Retroviruses (ed. J.M. Coffin et al.), p. 475. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
49. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
50. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., and Felsher D.W. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112.
51. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399.
52. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., Wistuba I.I., Fong K.M., Toyooka S., Shimizu N., Fujisawa T., Minna J.D., and Gazdar A.F. 2005. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65: 1642.
53. Siegel P.M., Dankort D.L., Hardy W.R., and Muller W.J. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068.
54. Sordella R., Bell D.W., Haber D.A., and Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163.
55. Stehelin D., Varmus H.E., Bishop J.M., and Vogt P.K. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170.
56. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M., Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A., Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K., Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K., Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T., Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R., and Stratton M.R. 2004. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431: 525.
57. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., Bignell G., Teague J., Smith R., Stevens C., O'Meara S., Parker A., Tarpey P., Avis T., Barthorpe A., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B., Yuen S.T., Nicholson A.G., Lakhani S., Easton D.F., Weber B.L., Stratton M.R., Futreal P.A., and Wooster R. 2005. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37: 590.
58. Tamborini E., Bonadiman L., Greco A., Albertini V., Negri T., Gronchi A., Bertulli R., Colecchia M., Casali P.G., Pierotti M.A., and Pilotti S. 2004. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294.
59. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. 2004. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64: 7241.
60. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J., and Shepherd F.A. 2005. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N. Engl. J. Med. 353: 133.
61. Wang R., Ferrell L.D., Faouzi S., Maher J.J., and Bishop J.M. 2001. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153: 1023.